Mutations in Bruton's tyrosine kinase impair IgA responses

被引:17
|
作者
Mitsuiki, Noriko [1 ]
Yang, Xi [2 ]
Bartol, Sophinus J. W. [3 ]
Grosserichter-Wagener, Christina [3 ]
Kosaka, Yoshiyuki [4 ]
Takada, Hidetoshi [5 ]
Imai, Kohsuke [1 ]
Kanegane, Hirokazu [2 ]
Mizutani, Shuki [1 ]
van der Burg, Mirjam [3 ]
van Zelm, Menno C. [3 ]
Ohara, Osamu [6 ,7 ]
Morio, Tomohiro [1 ]
机构
[1] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Pediat & Dev Biol, Bunkyo Ku, Tokyo 1138510, Japan
[2] Toyama Univ, Grad Sch Med & Pharmaceut Sci, Dept Pediat, Toyama 930, Japan
[3] Univ Med Ctr, Erasmus MC, Dept Immunol, Rotterdam, Netherlands
[4] Hyogo Prefectural Childrens Hosp, Dept Hematol Oncol, Kobe, Hyogo, Japan
[5] Kyushu Univ, Grad Sch Med Sci, Dept Pediat, Fukuoka 812, Japan
[6] Kazusa DNA Res Inst, Dept Human Genome Technol, Chiba, Japan
[7] RIKEN Res Ctr Allergy & Immunol, Lab Immunogen, Kanagawa, Japan
基金
日本学术振兴会;
关键词
Bruton's tyrosine kinase; X-linked agammaglobulinemia; IgA deficiency; Class switch recombination; Somatic hypermutation; X-LINKED AGAMMAGLOBULINEMIA; B-CELL DEVELOPMENT; COMMON VARIABLE IMMUNODEFICIENCY; TRANSMEMBRANE ACTIVATOR; ANTIGEN-RECEPTOR; BTK; DEFICIENCY; IMMUNOGLOBULIN; HETEROZYGOTES; STIMULATION;
D O I
10.1007/s12185-015-1732-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
X-linked agammaglobulinemia (XLA) is a primary immunodeficiency caused by mutations in Bruton's tyrosine kinase (BTK), and is characterized by markedly decreased numbers of blood B cells and an absence of all immunoglobulin isotypes. We performed whole exome sequencing in a male pediatric patient with dysgammaglobulinemia with IgA deficiency. Genetic analysis revealed a BTK missense mutation (Thr316Ala). To investigate whether a BTK mutation underlay this antibody deficiency with marked decrease of IgA in this patient, we performed functional analyses of B cells and phagocytes, and molecular analyses of somatic hypermutation and class switch recombination. The BTK missense mutation resulted in B cells with reduced BTK and high IgM expression. Equal proportions of CD19(low) and CD19(normal) fractions were observed, and both included na < ve and memory B cells. Calcium influx and phospholipase C gamma 2 phosphorylation upon IgM stimulation were marginally impaired in CD19(low), but not in CD19(+) B cells. Similar to XLA patients, IgA transcripts showed low SHM levels, whereas IgG transcripts were hardly affected. Our analyses suggest that the BTK mutation likely underlies the disease in this case, and that hypomorphic BTK mutations can result in normal circulating B cell numbers, but specifically impair IgA responses.
引用
收藏
页码:305 / 313
页数:9
相关论文
共 50 条
  • [41] Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells
    Wang, Xianhui
    Wong, Jason
    Sevinsky, Christopher J.
    Kokabee, Leila
    Khan, Faiza
    Sun, Yan
    Conklin, Douglas S.
    MOLECULAR CANCER THERAPEUTICS, 2016, 15 (09) : 2198 - 2208
  • [42] Bruton's tyrosine kinase is not essential for LPS-induced activation of human monocytes
    de Diego, Rebeca Perez
    Lopez-Granados, Eduardo
    Pozo, Maite
    Rodriguez, Cristina
    Sabina, Prado
    Ferreira, Antonio
    Fontan, Gurnersindo
    Garcia-Rodriguez, Maria Cruz
    Alemany, Susana
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2006, 117 (06) : 1462 - 1469
  • [43] Role of Bruton's tyrosine kinase inhibitors in HIV-1-infected cells
    Guendel, Irene
    Iordanskiy, Sergey
    Sampey, Gavin C.
    Van Duyne, Rachel
    Calvert, Valerie
    Petricoin, Emanuel
    Saifuddin, Mohammed
    Kehn-Hall, Kylene
    Kashanchi, Fatah
    JOURNAL OF NEUROVIROLOGY, 2015, 21 (03) : 257 - 275
  • [44] The Effects of Bruton Tyrosine Kinase Inhibition on Chemotaxis and Superoxide Generation in Human Neutrophils
    Broides, Arnon
    Hadad, Nurit
    Levy, Jacov
    Levy, Rachel
    JOURNAL OF CLINICAL IMMUNOLOGY, 2014, 34 (05) : 555 - 560
  • [45] A Novel Role for Bruton's Tyrosine Kinase in Hepatocyte Growth Factor-mediated Immunoregulation of Dendritic Cells
    Singhal, Eshu
    Kumar, Prakash
    Sen, Pradip
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, 286 (37) : 32054 - 32063
  • [46] Characterization of Bruton's tyrosine kinase mutations in Mexican patients with X-linked agammaglobulinemia
    Lopez-Herrera, G.
    Berron-Ruiz, L.
    Mogica-Martinez, D.
    Espinosa-Rosales, F.
    Santos-Argumedo, L.
    MOLECULAR IMMUNOLOGY, 2008, 45 (04) : 1094 - 1098
  • [47] Role of Bruton's Tyrosine Kinase in Stage III Colorectal Cancer
    Basile, Debora
    Gerratana, Lorenzo
    Buonadonna, Angela
    Garattini, Silvio Ken
    Perin, Tiziana
    Grassilli, Emanuela
    Miolo, Gianmaria
    Cerrito, Maria Grazia
    Belluco, Claudio
    Bertola, Giulio
    Paoli, Antonino De
    Cannizzaro, Renato
    Lavitrano, Marialuisa
    Puglisi, Fabio
    Canzonieri, Vincenzo
    CANCERS, 2019, 11 (06)
  • [48] Bruton's tyrosine kinase (BTK) as a promising target in solid tumors
    Molina-Cerrillo, J.
    Alonso-Gordoa, T.
    Gajate, P.
    Grande, E.
    CANCER TREATMENT REVIEWS, 2017, 58 : 41 - 50
  • [49] Clinical potential of targeting Bruton's tyrosine kinase
    Uckun, Fatih M.
    INTERNATIONAL REVIEWS OF IMMUNOLOGY, 2008, 27 (1-2) : 43 - 69
  • [50] Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases
    Marcotte, Douglas J.
    Liu, Yu-Ting
    Arduini, Robert M.
    Hession, Catherine A.
    Miatkowski, Konrad
    Wildes, Craig P.
    Cullen, Patrick F.
    Hong, Victor
    Hopkins, Brian T.
    Mertsching, Elisabeth
    Jenkins, Tracy J.
    Romanowski, Michael J.
    Baker, Darren P.
    Silvian, Laura F.
    PROTEIN SCIENCE, 2010, 19 (03) : 429 - 439